Literature DB >> 23354874

Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas.

Hiba el Sayadi1, Daniel Pissaloux, Laurent Alberti, Severine Tabone-Eglinger, Dominique Ranchere, Anne Valérie Decouvelaere, Eric Tabone, Isabelle Ray-Coquard, Christophe Caux, Jérome Fayette, Jean-Yves Blay.   

Abstract

Leiomyosarcoma (LMS) represent 15 % of adult sarcomas. The aim of this work was to identify novel altered pathways in LMS, which may be of therapeutic value for patients. Thirteen fresh frozen samples of soft tissue and visceral LMS were analyzed and compared with normal smooth muscle uterine tissue (NSM) for phosphoproteomic profile. Four proteins were found differentially expressed including Tyro3. The functional role of Tyro3 and its ligand Gas6 was investigated in two LMS cell lines, SK-LMS-1 and CNIO-AA. Four proteins and phosphoproteins were differentially expressed in LMS samples vs NSM: A loss of FAK Y397 phosphorylation was observed in all LMSs, while Tyro3, MSH2 and PKC theta were consistently overexpressed. Gas6, the major ligand of Tyro3, was expressed in 8 of the 13 LMS samples, and Gas6 expression highly correlated to Akt Y473 phosphorylation and to a lesser extent to Erk1/2 phosphorylation. SK-LMS-1 and CNIO-AA LMS expressed Tyro3, Axl and Gas6 at high level in CNIO-AA while at low levels in SK-LMS-1. Exposure of both cell lines to foretinib, a tyrosine kinase inhibitor of Met, Axl and Tyro3, reduced cell viability and induced caspase 3/7 activation. Transfection of CNIO-AA with small interfering RNA directed against Tyro3 and Axl genes induced a reduction of the expression of the specific proteins and, when combined, significantly reduced CNIO-AA cell viability. Leiomyosarcomas overexpress Tyro3. Gas6, a ligand of Tyro3, exerts an autocrine activities though Tyro3 and Axl in a subgroup of LMS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23354874     DOI: 10.1007/s11523-012-0249-2

Source DB:  PubMed          Journal:  Target Oncol        ISSN: 1776-2596            Impact factor:   4.493


  33 in total

Review 1.  Soft-tissue sarcomas in adults.

Authors:  Matthew A Clark; Cyril Fisher; Ian Judson; J Meirion Thomas
Journal:  N Engl J Med       Date:  2005-08-18       Impact factor: 91.245

Review 2.  Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Authors:  P G Casali; L Jost; S Sleijfer; J Verweij; J-Y Blay
Journal:  Ann Oncol       Date:  2009-05       Impact factor: 32.976

3.  PKC-theta expression in Ewing sarcoma/primitive neuroectodermal tumour and malignant peripheral nerve sheath tumour.

Authors:  Gu Hyun Kang; Kyoung-Mee Kim; Cheol Keun Park; Dae Young Kang
Journal:  Histopathology       Date:  2009-09       Impact factor: 5.087

4.  Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region.

Authors:  Antoine Lurkin; Francoise Ducimetière; Dominique Ranchère Vince; Anne-Valérie Decouvelaere; Dominic Cellier; François N Gilly; Dimitri Salameire; Pierre Biron; Guy de Laroche; Jean Yves Blay; Isabelle Ray-Coquard
Journal:  BMC Cancer       Date:  2010-04-19       Impact factor: 4.430

Review 5.  TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer.

Authors:  Rachel M A Linger; Amy K Keating; H Shelton Earp; Douglas K Graham
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

6.  Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).

Authors:  Stefan Sleijfer; Isabelle Ray-Coquard; Zsuzsa Papai; Axel Le Cesne; Michelle Scurr; Patrick Schöffski; Françoise Collin; Lini Pandite; Sandrine Marreaud; Annick De Brauwer; Martine van Glabbeke; Jaap Verweij; Jean-Yves Blay
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

7.  Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme.

Authors:  Markus Hutterer; Pjotr Knyazev; Ariane Abate; Markus Reschke; Hans Maier; Nadia Stefanova; Tatjana Knyazeva; Verena Barbieri; Markus Reindl; Armin Muigg; Herwig Kostron; Guenther Stockhammer; Axel Ullrich
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  KIT mutations induce intracellular retention and activation of an immature form of the KIT protein in gastrointestinal stromal tumors.

Authors:  Séverine Tabone-Eglinger; Frédéric Subra; Hiba El Sayadi; Laurent Alberti; Eric Tabone; Jean-Philippe Michot; Nathalie Théou-Anton; Antoinette Lemoine; Jean-Yves Blay; Jean-François Emile
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

9.  A genomic screen identifies TYRO3 as a MITF regulator in melanoma.

Authors:  Shoutian Zhu; Heiko Wurdak; Yan Wang; Anna Galkin; Haiyan Tao; Jie Li; Costas A Lyssiotis; Feng Yan; Buu P Tu; Loren Miraglia; John Walker; Fanxiang Sun; Anthony Orth; Peter G Schultz; Xu Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

10.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Authors:  Robert G Maki; J Kyle Wathen; Shreyaskumar R Patel; Dennis A Priebat; Scott H Okuno; Brian Samuels; Michael Fanucchi; David C Harmon; Scott M Schuetze; Denise Reinke; Peter F Thall; Robert S Benjamin; Laurence H Baker; Martee L Hensley
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544

View more
  8 in total

Review 1.  Targeting protein kinases to reverse multidrug resistance in sarcoma.

Authors:  Hua Chen; Jacson Shen; Edwin Choy; Francis J Hornicek; Zhenfeng Duan
Journal:  Cancer Treat Rev       Date:  2015-12-08       Impact factor: 12.111

Review 2.  Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?

Authors:  Wout De Wispelaere; Daniela Annibali; Sandra Tuyaerts; Diether Lambrechts; Frédéric Amant
Journal:  Cancers (Basel)       Date:  2021-04-23       Impact factor: 6.639

3.  The role of AXL and the in vitro activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma.

Authors:  Emmy D G Fleuren; Melissa H S Hillebrandt-Roeffen; Uta E Flucke; D Maroeska W M Te Loo; Otto C Boerman; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers
Journal:  Oncotarget       Date:  2014-12-30

Review 4.  Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma.

Authors:  Hideaki Tsuyoshi; Yoshio Yoshida
Journal:  Cancer Sci       Date:  2018-05-23       Impact factor: 6.716

5.  TYRO3 as a molecular target for growth inhibition and apoptosis induction in bladder cancer.

Authors:  Florent Dufour; Linda Silina; Hélène Neyret-Kahn; Aura Moreno-Vega; Clémentine Krucker; Narjesse Karboul; Marion Dorland-Galliot; Pascale Maillé; Elodie Chapeaublanc; Yves Allory; Nicolas Stransky; Hélène Haegel; Thierry Menguy; Vanessa Duong; François Radvanyi; Isabelle Bernard-Pierrot
Journal:  Br J Cancer       Date:  2019-02-15       Impact factor: 7.640

6.  ssExpression level of GAS6-mRNA influences the prognosis of acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation.

Authors:  Xinrui Yang; Jinlong Shi; Xinpei Zhang; Gaoqi Zhang; Jilei Zhang; Siyuan Yang; Jing Wang; Xiaoyan Ke; Lin Fu
Journal:  Biosci Rep       Date:  2019-05-21       Impact factor: 3.840

Review 7.  The Emerging Role of TYRO3 as a Therapeutic Target in Cancer.

Authors:  Sherri K Smart; Eleana Vasileiadi; Xiaodong Wang; Deborah DeRyckere; Douglas K Graham
Journal:  Cancers (Basel)       Date:  2018-11-29       Impact factor: 6.639

8.  Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma.

Authors:  Carmela Dantas-Barbosa; Tom Lesluyes; François Le Loarer; Fréderic Chibon; Isabelle Treilleux; Jean-Michel Coindre; Pierre Meeus; Mehdi Brahmi; Olivia Bally; Isabelle Ray-Coquard; Marie-Pierre Sunyach; Axel Le Cesne; Olivier Mir; Sylvie Bonvalot; Maud Toulmonde; Antoine Italiano; Pierre Saintigny; Myriam Jean-Denis; Francoise Ducimetiere; Dominique Ranchere; Hiba El Sayadi; Laurent Alberti; Jean-Yves Blay
Journal:  Br J Cancer       Date:  2017-10-12       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.